Research Summary: The following information is provided for research context only.
Semaglutide Research Overview
Semaglutide is a GLP-1 receptor agonist analogue with an extended half-life relative to native GLP-1, achieved through fatty acid modification that enables albumin binding and resistance to DPP-4 enzymatic degradation. It is one of the most widely characterized reference compounds in in-vitro incretin and receptor-signaling research.
Mechanism of Action
Semaglutide binds to GLP-1 receptors expressed in pancreatic beta-cell, hypothalamic, and gastrointestinal tissue models. Receptor activation drives glucose-dependent insulinotropic signaling and downstream cAMP pathway activity. Its prolonged half-life makes it a useful reference compound for studying sustained GLP-1 receptor engagement in preclinical in-vitro models.
Research Applications
Semaglutide is commonly used as a reference compound in in-vitro GLP-1 receptor-binding assays, comparative incretin agonist studies, and receptor-signaling characterization alongside Tirzepatide and Retatrutide.
Compound Specifications
Lyophilized Semaglutide 10mg at 99%+ HPLC-UV purity. LCMS-confirmed identity. Molecular weight: 4113.6 Da. Batch SEM010-001. COA included with every order.
Storage and Handling
Store at -20°C prior to reconstitution. Reconstitute with sterile bacteriostatic water. Once in solution, store at 4°C and use within 28 days.
For research use only. Not for human or veterinary use.
Reviews
There are no reviews yet.